FindTrial
Sign In

LACTIN-V

DRUG4 trials

Sponsors

University of Washington, Osel, Inc., Imperial College London, University of California, San Francisco

Conditions

Bacterial VaginosisCervical IncompetenceHIV InfectionsMiscarriage in Second TrimesterMiscarriage in Third TrimesterPreterm BirthPreterm LaborPreterm Premature Rupture of Membrane

Phase 1

The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
NCT03992534
Imperial College LondonCervical Incompetence, Miscarriage in Second Trimester, Miscarriage in Third Trimester +3
Start: 2019-09-16End: 2021-10-01Target: 60Updated: 2020-05-28

Phase 2

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
CompletedNCT00305227
University of WashingtonUrinary Tract Infection
Start: 2006-03-31End: 2012-04-30Updated: 2023-04-14
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
CompletedNCT00635622
Osel, Inc.Bacterial Vaginosis
Start: 2008-04-30End: 2009-01-31Target: 40Updated: 2009-07-10
Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition
CompletedNCT05022212
University of California, San FranciscoBacterial Vaginosis, HIV Infections
Start: 2021-05-10End: 2023-03-31Updated: 2024-08-13

Related Papers

Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial.
2025-04-049 citations
Acceptability of the live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) among young women at high risk of HIV acquisition in South Africa: data from the phase 2 placebo-controlled trial
Frontiers in Reproductive Health2025-03-251 citations
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.
2011-04-14308 citations